一种用于SARS-CoV-2血清学和药物筛选的体外微量中和试验。
An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
作者信息
Amanat Fatima, White Kris M, Miorin Lisa, Strohmeier Shirin, McMahon Meagan, Meade Philip, Liu Wen-Chun, Albrecht Randy A, Simon Viviana, Martinez-Sobrido Luis, Moran Thomas, García-Sastre Adolfo, Krammer Florian
机构信息
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Curr Protoc Microbiol. 2020 Sep;58(1):e108. doi: 10.1002/cpmc.108.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1: Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2: Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol: SARS-CoV-2 propagation.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）于2019年末在中国湖北省武汉市出现。从那时起，该病毒已在全球传播并引发了一场大流行。SARS-CoV-2疫苗和药物研发需要能够测量抗体或抗病毒化合物抗病毒活性的检测方法。在此，我们详细描述一种微量中和试验，该试验可用于以定量方式评估抗体或药物是否能在体外阻断SARS-CoV-2的进入和/或复制。© 2020威利期刊有限责任公司。基本方案1：用抗体（纯化抗体或血清/血浆）检测病毒抑制作用的微量中和试验 基本方案2：体外抗SARS-CoV-2化合物的筛选 支持方案：SARS-CoV-2繁殖。
Zotero 插件